Subcutaneous (SC) atezolizumab is in development for the treatment of patients with metastatic or locally advanced non-small-cell lung cancer (NSCLC) who have previously received treatment. NSCLC is the most common type of cancer found in the lungs and is often caused by things such as smoking. Advanced or metastatic NSCLC means that the cancer has spread to other parts of the body, making it harder to treat. Existing treatment options for previously treated NSCLC are all administered via intravenous (IV) infusion, which means patients often spend hours receiving treatment in hospitals.
Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer
Subcutaneous (SC) atezolizumab is in development for the treatment of patients with metastatic or locally advanced non-small-cell lung cancer (NSCLC) who have previously received treatment. NSCLC is the most common type of cancer found in the lungs and is often caused by things such as smoking.
Interventions:
Atezolizumab (Tecentriq; MPDL3280A)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2022